The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye
This trial is active, not recruiting.
|Conditions||glaucoma, periocular skin pigmentation changes|
|Treatments||latanoprost, bimatoprost, travoprost|
|Sponsor||Summa Health System|
|Start date||March 2008|
|End date||December 2012|
|Trial size||75 participants|
|Trial identifier||NCT00705757, Pfizer GA6111AX|
The purpose of this study is to study changes in skin color that may be caused by using one of the three eye medicines: Xalatan, Travatan or lumigan.
|Intervention model||parallel assignment|
|Masking||single blind (outcomes assessor)|
skin pigmentation changes
time frame: one year
Male or female participants at least 30 years old.
Inclusion Criteria: - patients recently diagnosed with primary open angle glaucoma or ocular hypertension - Caucasian and African American ethnicities - Male and Female - Age 30 and above Exclusion Criteria: - A history of ocular medication use within the last 12 months - Inflammatory/ allergic skin diseases or dermatitis - presence of periocular hyperpigmented skin lesions - Systemic pigmentation disorders - Use of systemic drugs that can affect skin pigmentation - Visitation of tanning salons, or use of self tanning products - Pregnancy or patients planning to become pregnant in the near future
|Official title||The Effects of Latanoprost, Bimatoprost and Travoprost on Periocular Skin Pigmentation|
|Principal investigator||Deepak P Edward, MD|
|Description||One uncommon side effect of prostaglandin eye drops is a change in color of the skin around the eyes, which is reversible. There are three different brands of the medicine which are equally effective in lowering eye pressure but their likelihood of changing skin color is unknown. Qualifying patients will be randomly assigned to use one of the three eye drops. We will take skin color measurements from several locations on the face over one year to measure pigmentation changes.|
Call for more information